Calculated Coronary Heart Disease Risk Research Articles

Changes in coronary heart disease risk profiles of HIV patients in Zimbabwe over 9 months: a follow-up study.

Dyslipidemia, hypertension, inflammation, and coronary heart disease (CHD) are adverse events in human immunodeficiency virus (HIV)-infected patients even if they are receiving antiretroviral therapy (ART). Yet, data on CHD risk induced by HIV or ART in sub-Saharan Africa are limited. The aim of this longitudinal study was to describe changes in CHD risk profiles measured by lipids, inflammatory markers, and Framingham scores among HIV-positive patients previously reported from Harare, Zimbabwe. Patients were grouped into ART-experienced patients (n=147) and ART-naïve patients (n=23) and followed up for 9 months. Generalized least squares random-effects modeling was applied to explain changes in total cholesterol (TC), high-density lipoprotein (HDL), low-density lipoprotein, TC/HDL ratio, myeloperoxidase, highly sensitive C-reactive protein, and Framingham scores over the 9-month period. Independent variables included age, sex, monthly earning, body mass index, systolic blood pressure (SBP), diastolic blood pressure, duration of HIV diagnosis, duration of ART, viral load, and CD4 count. In ART-experienced patients, there was a substantial decrease in TC over time, ART-negative patients showed a significant increase in TC and HDL over time, and the increase in TC was associated with high viral load and low duration of HIV diagnosis, while increase in HDL was associated with young age, low body mass index, and low SBP. Framingham risk scores increased with time in ART-positive patients, and the change was positively correlated with age, sex, high SBP, and low HDL. There was no association between calculated CHD risk (TC/HDL ratio or Framingham score) and changes in levels of inflammatory markers (myeloperoxidase and highly sensitive C-reactive protein) in any of the patient groups. In conclusion, ART-experienced HIV-positive patients show changes in lipid values over time that makes it necessary to include lipid monitoring in order to reduce any risk of long-term CHD.

Nut consumption, serum fatty acid profile and estimated coronary heart disease risk in type 2 diabetes

Background and aimsNut consumption has been associated with decreased risk of coronary heart disease (CHD) and type 2 diabetes which has been largely attributed to their healthy fatty acid profile, yet this has not been ascertained. Therefore, we investigated the effect of nut consumption on serum fatty acid concentrations and how these relate to changes in markers of glycemic control and calculated CHD risk score in type 2 diabetes. Methods and results117 subjects with type 2 diabetes consumed one of three iso-energetic (mean 475 kcal/d) supplements for 12 weeks: 1. full-dose nuts (50–100 g/d); 2. half-dose nuts with half-dose muffins; and 3. full-dose muffins. In this secondary analysis, fatty acid concentrations in the phospholipid, triacylglycerol, free fatty acid, and cholesteryl ester fractions from fasting blood samples obtained at baseline and week 12 were analyzed using thin layer and gas chromatography. Full-dose nut supplementation significantly increased serum oleic acid (OA) and MUFAs compared to the control in the phospholipid fraction (OA: P = 0.036; MUFAs: P = 0.024). Inverse associations were found with changes in CHD risk versus changes in OA and MUFAs in the triacylglycerol (r = −0.256, P = 0.011; r = −0.228, P = 0.024, respectively) and phospholipid (r = −0.278, P = 0.006; r = −0.260, P = 0.010, respectively) fractions. In the cholesteryl ester fraction, change in MUFAs was inversely associated with markers of glycemic control (HbA1c: r = −0.250, P = 0.013; fasting blood glucose: r = −0.395, P < 0.0001). ConclusionNut consumption increased OA and MUFA content of the serum phospholipid fraction, which was inversely associated with CHD risk factors and 10-year CHD risk. Clinical Trial Reg. No.NCT00410722, clinicaltrials.gov.

Reduction in cardiovascular risk using a proactive multifactorial intervention is consistent among patients residing in Pacific Asian and non-Pacific Asian regions: a CRUCIAL trial subanalysis

BackgroundFew trials have compared different approaches to cardiovascular disease prevention among Pacific Asian (PA) populations. The Cluster Randomized Usual Care versus Caduet Investigation Assessing Long-term-risk (CRUCIAL) trial demonstrated that a proactive multifactorial intervention (PMI) approach (based on single-pill amlodipine/atorvastatin) resulted in a greater reduction in calculated Framingham 10-year coronary heart disease (CHD) risk compared with usual care (UC) among hypertensive patients with additional risk factors. One-third of CRUCIAL patients resided in the PA region. The aim of this subanalysis was to compare two approaches to cardiovascular risk factor management (PMI versus UC) among patients residing in PA and non-PA regions.MethodsThis subanalysis of the CRUCIAL trial compared treatment-related changes in calculated CHD risk among patients residing in PA and non-PA regions. Sensitivity analyses were conducted among men and women and those with and without diabetes.ResultsOverall, 448 patients (31.6%) resided in the PA region and 969 patients (68.4%) resided in non-PA regions. The PMI approach was more effective in reducing calculated CHD risk versus UC in both PA (−37.1% versus −3.5%; P<0.001) and non-PA regions (−31.1% versus −4.2%; P<0.001); region interaction P=0.131. PA patients had slightly greater reductions in total cholesterol compared with non-PA patients. PA patients without diabetes had slightly greater reductions in CHD risk compared with non-PA patients. Treatment effects were similar in men and women and those with diabetes.ConclusionThe PMI approach was more effective in reducing calculated Framingham 10-year CHD risk compared with UC among men and women with and without diabetes residing in the PA and non-PA region.

Preventable Coronary Heart Disease Events from Control of Cardiovascular Risk Factors in US Adults With Diabetes (Projections from Utilizing the UKPDS Risk Engine)

Type 2 diabetes mellitus (T2DM) carries significant risks for coronary heart disease (CHD). We examined the potential US population impact of single and composite risk factor control. Among US adults with diagnosed T2DM aged≥30 years in the National Health and Nutrition Examination Survey 2007 to 2012, we assessed CHD events preventable using the United Kingdom Prospective Diabetes Study CHD risk engine. We examined in all those not at goal the impact of statistical control of smoking, glycated hemoglobin, systolic blood pressure, and total and high-density lipoprotein cholesterol, according to the predefined criteria setting risk factors at different levels of control representing (1) "All to Goal," (2) at "Nominal Control," or (3) at "Aggressive Control." Preventable CHD events represented the difference between the number of events estimated from the control of these risk factors versus current levels of the risk factors. Of 606 men (representing 6.2 million) and 603 women (6.3 million) with DM and no previous CHD, 1.3 million men and 0.7 million women would develop a CHD event within 10 years if left uncontrolled. Controlling all risk factors to goal was projected to prevent 35% and 45% of CHD events in men and women, respectively. Nominal risk factor control was projected to prevent 36% and 38% and aggressive control 51% and 61% of CHD events, respectively. In conclusion, a significant proportion of CHD events in adults with T2DM could be prevented from composite control of risk factors often not at goal.

Reduction in cardiovascular risk using proactive multifactorial intervention versus usual care in younger (

Objective:To compare the reduction in calculated Framingham 10 year coronary heart disease (CHD) risk after 52 weeks’ intervention with a proactive multifactorial intervention (PMI) strategy (based on single-pill amlodipine/atorvastatin [SPAA]) versus continuing usual care (UC) (based on investigators' best clinical judgment) among younger (<65 years) and older (≥65 years) patients.Research design and methods:Sub-analysis of the Cluster Randomized Usual Care versus Caduet Investigation Assessing Long-term risk (CRUCIAL) trial. Eligible patients had hypertension and ≥3 cardiovascular risk factors.Main outcome measure:Treatment-related reduction in calculated Framingham 10 year CHD risk between baseline and Week 52 in younger and older patients.Results:Nine hundred patients (63.5%) were <65 years (mean age 54.2 years, 57.4% men) and 517 patients (36.5%) were ≥65 years (mean age 70.5 years, 42.7% men). Younger patients had lower mean baseline CHD risk versus older patients (17.1% vs. 22.6%). A greater reduction in calculated CHD risk at Week 52 was observed in the PMI versus the UC arm in both younger (−33.2% vs. −2.9%, p < 0.001) and older (−32.7% vs. −5.7%, p < 0.001) patients. Least-squares mean treatment differences (PMI vs. UC) in percentage change from baseline in calculated CHD risk were similar in younger and older patients (−26.3% vs. −25.7%, age interaction p = 0.887). CHD risk reduction was slightly greater among younger men than younger women (−29.3 vs. −23.9, gender interaction p = 0.062). A low proportion of patients discontinued the PMI strategy due to adverse events in both age groups (5.8% vs. 6.1%, respectively). Study limitations included ad-hoc (not pre-specified) sub-group analysis and short duration of follow-up.Conclusions:The PMI strategy based on the inclusion of SPAA in the treatment regimen is more effective than UC in reducing calculated CHD risk. This strategy may be considered as the treatment of choice in younger and older hypertensive patients with additional cardiovascular risk factors.

Effect of Legumes as Part of a Low Glycemic Index Diet on Glycemic Control and Cardiovascular Risk Factors in Type 2 Diabetes Mellitus

Legumes, including beans, chickpeas, and lentils, are among the lowest glycemic index (GI) foods and have been recommended in national diabetes mellitus (DM) guidelines. Yet, to our knowledge, they have never been used specifically to lower the GI of the diet. We have therefore undertaken a study of low-GI foods in type 2 DM with a focus on legumes in the intervention. A total of 121 participants with type 2 DM were randomized to either a low-GI legume diet that encouraged participants to increase legume intake by at least 1 cup per day, or to increase insoluble fiber by consumption of whole wheat products, for 3 months. The primary outcome was change in hemoglobin A1c (HbA1c) values with calculated coronary heart disease (CHD) risk score as a secondary outcome. The low-GI legume diet reduced HbA1c values by -0.5% (95% CI, -0.6% to -0.4%) and the high wheat fiber diet reduced HbA1c values by -0.3% (95% CI, -0.4% to -0.2%). The relative reduction in HbA1c values after the low-GI legume diet was greater than after the high wheat fiber diet by -0.2% (95% CI, -0.3% to -0.1%; P < .001). The respective CHD risk reduction on the low-GI legume diet was -0.8% (95% CI, -1.4% to -0.3%; P = .003), largely owing to a greater relative reduction in systolic blood pressure on the low-GI legume diet compared with the high wheat fiber diet (-4.5 mm Hg; 95% CI, -7.0 to -2.1 mm Hg; P < .001). Incorporation of legumes as part of a low-GI diet improved both glycemic control and reduced calculated CHD risk score in type 2 DM.

Changes in calculated coronary heart disease risk using proactive multifactorial intervention versus continued usual care in Latin-American and non-Latin-American patients enrolled in the CRUCIAL trial

Objective:To compare the change in calculated coronary heart disease (CHD) risk using a proactive multifactorial intervention (PMI) versus usual care (UC), among Latin-American (LA) and non-LA patients enrolled in the CRUCIAL trial.Research design and methods:This is a sub-analysis of the Cluster Randomized Usual Care versus Caduet Investigation Assessing Long-term-risk (CRUCIAL) trial. CRUCIAL was a prospective, multinational, open-label, cluster-randomized trial. Eligible patients had hypertension and ≥3 additional cardiovascular risk factors, but no history of CHD and baseline total cholesterol ≤6.5 mmol/l (250 mg/dl). The PMI strategy was implemented by the inclusion of single-pill amlodipine/atorvastatin (SPAA) in the patients’ treatment regimen. Overall, 20% of patients resided in the LA region.Main outcome measure:Treatment-related change in calculated Framingham 10-year CHD risk between baseline and Week 52 in the LA and non-LA regions.Results:A greater relative reduction in calculated CHD risk after 52 weeks’ follow-up was observed for patients in the PMI arm compared with UC arm in both LA (−32.8% vs. −7.5%, p = 0.003) and non-LA regions (−33.1% vs. −3.3%, p < 0.001), region interaction p = 0.316. The proportion of patients discontinuing treatment in the PMI arm due to adverse events (AEs) was low in both regions (both 5.9%).Conclusions:The PMI approach based on the inclusion of SPAA in the patients’ treatment regimen may improve the management of CHD risk among patients residing in LA and non-LA regions. Clinicians may be reassured by the low rate of AEs leading to discontinuation of SPAA in both regions.

Quality of Parental Emotional Care and Calculated Risk for Coronary Heart Disease

To evaluate associations between perceived quality of parental emotional care and calculated 10-year risk for coronary heart disease (CHD). Little is understood about the role of parental emotional care in contributing to the risk for CHD. The study sample was composed of 267 participants from the New England Family Study. Quality of parental emotional care was measured, using a validated short version of the Parental Bonding Instrument (PBI) as the average care scores for both parents (range = 0-12), with higher scores indicating greater care. Ten-year CHD risk was calculated, using the validated Framingham Risk Algorithm that incorporates the following prevalent CHD risk factors: age, sex, diabetes, smoking, total cholesterol, high-density lipoprotein cholesterol, and blood pressure. Multiple linear regression assessed associations of PBI with calculated CHD risk after adjusting for childhood socioeconomic status, depressive symptomatology, educational attainment, and body mass index. Among females, a 1-unit increase in the parental emotional care score resulted in a 4.6% (p = .004) decrease in the 10-year CHD risk score, after adjusting for covariates. There was no association between parental emotional care score and calculated CHD risk score in males (p = .22). Quality of parental emotional care was inversely associated with calculated 10-year CHD risk in females, and not males. Although the gender differences need further investigation and these findings require replication, these results suggest that the early childhood psychosocial environment may confer risk for CHD in adulthood.

Factors predicting the development of metabolic syndrome and type II diabetes against a background of hypertension

The metabolic syndrome (MetS), predicting coronary heart disease (CHD), is a compound of risk factors including diabetes, obesity and hypertension. The relationship between the development of MetS, diabetes and CHD in patients with established hypertension is unclear. We hypothesized that patients with hypertension developing MetS are at increased risk of type II diabetes and CHD compared with patients who do not develop MetS. We prospectively studied 284 patients (100 with existing/established MetS) with hypertension but without diabetes and CHD over 4 years. MetS and diabetes were diagnosed by the modified NCEP and ADA criteria, and CHD risk by the Framingham risk equation; all patients had annual fasting blood sampling. Over 4 years of follow up, 75 of the 184 patients (41%) initially free of MetS at baseline subsequently fulfilled the criteria for MetS. These patients (i.e. 'developing MetS') had higher baseline BMI, triglycerides and lower HDL cholesterol, with a higher calculated CHD risk (all P <or= 0.001) than those who did not develop MetS. The 4-year odds ratios of developing diabetes in the patients with established MetS (23%) and the patients developing MetS (13.3%) vs. the patients not developing MetS (3.7%, P < 0.001) were 7.8 (95% CI: 2.6-23.5) and 4.0 (95% CI: 1.2-13.4), respectively. Patients with hypertension developing MetS have an increased CHD risk and risk of developing type II diabetes even before fulfilling the criteria for MetS, and the former is comparable to patients with established MetS. These data suggest a high-risk phase not adequately identified by current diagnostic thresholds for MetS.

A high risk score for coronary heart disease is associated with the metabolic syndrome in 40-year-old men and women.

Guidelines recommend follow-up of people whose 10-year risk of coronary heart disease (CHD) is > 10%. We calculated CHD risk, number of risk factors and occurrence of the metabolic syndrome among screened 40-year-old men and women. A total of 1547 women and 1374 men participated in a cardiovascular risk factor screening programme in 1997-1999 in Oslo. Of 387 (13%) recalled for further examination and advice, 337 (87%) attended. We used the National Cholesterol Education Program criteria to define the metabolic syndrome and the Framingham risk score to assess absolute 10-year risk of CHD and counted nine risk factors (male, southeast-Asian origin, low education, smoking, premature familial cardiovascular disease (CVD), hypertension, high waist circumference, impaired fasting glucose or diabetes and high apolipoprotein B). More than one-third of subjects recalled for hypertension (n = 88) or low high-density lipoprotein (HDL) cholesterol (n = 95) had the metabolic syndrome. Of 55 subjects with a 10-year risk score > 10%, 33 (60%) had the metabolic syndrome. Subjects with the metabolic syndrome had a higher risk score compared with their counterparts (P < 0.001); among men with the metabolic syndrome, the mean +/- SD risk score was 10.0 +/- 4.4%. Subjects with dyslipidaemia [high triglyceride and normal low-density lipoprotein (LDL) cholesterol levels] or combined hyperlipidaemia had a higher risk score and more risk factors compared with subjects with isolated high LDL cholesterol (P < 0.05). Only 12% of subjects with hypertension were taking drugs and of 237 subjects with a lipid disorder, 30% had been given dietary advice and one was taking a lipid-lowering drug. CVD screening should focus on identifying people with features of the metabolic syndrome in this age group. The screening programme uncovered a substantial potential for CVD prevention.

A High Risk Score for Coronary Heart Disease is Associated with the Metabolic Syndrome in 40-year-old Men and Women

Guidelines recommend follow-up of people whose 10-year risk of coronary heart disease (CHD) is > 10%. We calculated CHD risk, number of risk factors and occurrence of the metabolic syndrome among screened 40-year-old men and women.A total of 1547 women and 1374 men participated in a cardiovascular risk factor screening programme in 1997-1999 in Oslo. Of 387 (13%) recalled for further examination and advice, 337 (87%) attended. We used the National Cholesterol Education Program criteria to define the metabolic syndrome and the Framingham risk score to assess absolute 10-year risk of CHD and counted nine risk factors (male, southeast-Asian origin, low education, smoking, premature familial cardiovascular disease (CVD), hypertension, high waist circumference, impaired fasting glucose or diabetes and high apolipoprotein B).More than one-third of subjects recalled for hypertension (n = 88) or low high-density lipoprotein (HDL) cholesterol (n = 95) had the metabolic syndrome. Of 55 subjects with a 10-year risk score > 10%, 33 (60%) had the metabolic syndrome. Subjects with the metabolic syndrome had a higher risk score compared with their counterparts (P < 0.001); among men with the metabolic syndrome, the mean +/- SD risk score was 10.0 +/- 4.4%. Subjects with dyslipidaemia [high triglyceride and normal low-density lipoprotein (LDL) cholesterol levels] or combined hyperlipidaemia had a higher risk score and more risk factors compared with subjects with isolated high LDL cholesterol (P < 0.05). Only 12% of subjects with hypertension were taking drugs and of 237 subjects with a lipid disorder, 30% had been given dietary advice and one was taking a lipid-lowering drug.CVD screening should focus on identifying people with features of the metabolic syndrome in this age group. The screening programme uncovered a substantial potential for CVD prevention.

Doxazosin and atenolol as monotherapy in mild and moderate hypertension: A randomized, parallel study with a three-year follow-up

The efficacy and safety of doxazosin ( n = 83) and atenolol ( n = 81) have been compared during a 3-year period. Doxazosin (mean dose at 3 years, 5.2 mg/day) and atenolol (mean dose, 66.4 mg/day) produced a sustained and overall similar reduction in blood pressure, with no evidence of tolerance. Doxazosin decreased mean blood pressure from 158 104 mm Hg to 146 90 mm Hg ; with atenolol the decrease was from 160 103 mm Hg to 144 88 mm Hg . Whereas the reduction in blood pressure with atenolol was paralleled by a significant ( p < 0.05) decrease in heart rate (from a mean of 74 to 60 beats/min), doxazosin produced no clinically meaningful changes in heart rate. In contrast to atenolol, doxazosin reduced triglyceride levels by −5.9% (atenolol +22.5%), increased high-density lipoprotein cholesterol levels by +3.7% (atenolol, −11.2%), and increased the high-density lipoprotein/total cholesterol ratio by +5.9% (atenolol, −10.3%); all of these values were significantly ( p < 0.001) different from those of atenolol-treated patients. Doxazosin also reduced the calculated low-density lipoprotein cholesterol levels by −3.3% (atenolol, unchanged). The adverse effect of atenolol on lipid levels apparently negated any beneficial effect of blood pressure reduction, because the calculated coronary heart disease (CHD) risk actually increased significantly. In contrast, the reduction in calculated CHD risk in the doxazosin group was statistically significant at all points during the study. The safety profile of the drugs was similar. With the added potential of the reduction in the calculated risk of CHD among hypertensive patients, doxazosin represents an appropriate first-line drug for the treatment of essential hypertension.

Doxazosin versus atenolol: A randomized comparison of calculated coronary heart disease risk reduction

Doxazosin is a selective α 1-inhibitor for the reduction of calculated coronary heart disease (CHD) risk in hypertensive patients. Atenolol, although a widely used β-blocker, appears to adversely affect blood lipids by increasing triglycerides and decreasing high-density lipoprotein (HDL) cholesterol. The aim of our study was to compare doxazosin and atenolol for their therapeutic efficacy in reducing CHD risk (decrease in blood pressure and effect on lipid distribution) and toleration. Patients with mild-to-moderate hypertension were randomized into two groups of 20 patients to receive once-daily atenolol (100 mg) or doxazosin (2 to 8 mg) for 8 weeks. Doxazosin was as effective as atenolol in reducing supine and standing blood pressure. Unlike atenolol, doxazosin did not produce a marked bradycardia. Doxazosin therapy produced favorable modifications in plasma lipid profiles by decreasing triglycerides and total cholesterol and by increasing HDL cholesterol and HDL/total cholesterol ratio. A reverse in this lipid profile was seen with atenolol. Therefore doxazosin may reduce calculated CHD risk more effectively than atenolol, based on the Framingham equation.

Clinical experience with doxazosin in general medical practice

The antihypertensive efficacy, lipid effects, and safety of doxazosin, a selective α 1-inhibitor for the reduction of coronary heart disease (CHD) risk in hypertensive patients, was assessed in a general medical practice setting. Seven hundred seventy-one patients were entered into the study, which involved three phases: (1) a 2-week baseline period, (2) an 8-week period in which patients received doxazosin, 1 to 8 mg once daily, and (3) a 4-week maintenance period. From baseline to final visit there was a highly significant 27% reduction (p <0.001) in calculated CHD risk based on the Framingham equation as a consequence of doxazosin's favorable effects on both blood pressure and serum lipid levels. Efficacy and toleration of doxazosin therapy were good to excellent in most patients. The investigators' global assessment of efficacy of once-daily doxazosin therapy was excellent or good for 82% of patients and fair or poor for only 18% of patients. After 12 weeks, 83% of the patients were considered therapy successes (sitting diastolic blood pressure either ≤90 mm Hg or ≥ 10 mm Hg reduction not reaching ≤90 mm Hg) at a mean daily dose of 3.5 mg. Seventy-one percent achieved “normalized” blood pressure control (sitting diastolic ≤90 mm Hg with a decrease of ≥5 mm Hg) at a mean dose of 3.1 mg once daily. By the final treatment visit, systolic/diastolic blood pressures of efficacy evaluable patients were reduced by 20.6 15.3 and 21.0 15.4 mm Hg from a mean baseline of 166 104 and 165 104 mm Hg in the sitting and standing positions, respectively (p < 0.05). Total cholesterol was significantiy decreased (p < 0.01). Most side effects were mild or moderate and disappeared with or were tolerated on continued therapy. The investigators' global assessment of patient toleration of doxazosin treatment was excellent or good for 89% of the 763 patients evaluated and fair or poor for only 11% of patients. The most commonly reported side effects were headache (8%) and dizziness (7%). No clinically significant laboratory changes were apparent, and no trends were observed with regard to organ systems or correlations with dose or duration of treatment.